Salīdzināt metodes

	MDS-UPDRS	EDSS: Kurtzke paplašinātā invaliditātes skalas	NIHSS: Nacionālo veselības institūtu insultu skala	RMI: Rivermead Mobility Index
Nozare	Neiroloģija	Neiroloģija	Neiroloģija	Neiroloģija
Saime	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
Izcelsmes gads	2008	1983	1989	1991
Autors	Christopher G. Goetz and Movement Disorder Society	John F. Kurtzke	Thomas Brott and NIH Stroke Study Group	Frank Collen, Derick Wade, and Rivermead Rehabilitation Centre
Tips	Clinician-rated	Clinician-rated	Clinician-rated	Clinician-observed performance test
Pirmavots	Goetz, C. G., et al. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 23(15), 2129-2170.	Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33(11), 1444-1452.	Brott, T., Adams, H. P., Olinger, C. P., et al. (1989). Measurements of acute cerebral infarction: A clinical examination scale. Stroke, 20(7), 864-870.	Collen, F. M., Wade, D. T., Robb, G. F., Bradshaw, C. M. (1991). The Rivermead Mobility Index: A further development of the Rivermead Motor Assessment. International Disability Studies, 13(2), 50-54.
Citi nosaukumi	UPDRS	Expanded Disability Status Scale	NIH Stroke Scale	Rivermead Mobility Index
Saistītās	5	4	5	5
Kopsavilkums	The MDS-UPDRS is the gold-standard clinician-administered rating scale for assessing motor and non-motor manifestations of Parkinson's disease. Developed by the Movement Disorder Society in 2008 to enhance the original UPDRS, it measures disease severity across daily living, motor function, and treatment complications. Used globally in clinical trials, longitudinal cohort studies, and routine neurological practice.	The EDSS is the most widely used clinical disability rating scale in multiple sclerosis research and practice. Developed by John Kurtzke in 1983, it provides a 0-10 ordinal scale capturing disease severity across eight neurological functional systems and functional status. The EDSS remains the primary endpoint in MS clinical trials and longitudinal cohort studies, with decades of prognostic and comparative data worldwide.	The NIHSS is the standard acute stroke severity assessment tool used in emergency departments, stroke centers, and clinical trials worldwide. Developed by the NIH Stroke Study Group in 1989, the 15-item scale provides rapid, reproducible quantification of acute neurological deficit from ischemic or hemorrhagic stroke. NIHSS scores inform thrombolytic and thrombectomy eligibility, predict outcomes, and serve as primary endpoint in stroke intervention trials.	The Rivermead Mobility Index (RMI) is a brief, clinician-observed performance test of basic mobility abilities developed for assessing stroke and neurological rehabilitation outcomes. Published in 1991 by Frank Collen and colleagues at Rivermead Rehabilitation Centre (Oxford, UK), the 15-item index measures bed mobility, sitting/standing balance, transfers, and ambulation. The RMI is widely used in stroke units and rehabilitation settings to track functional recovery and predict discharge outcomes.